Antagonist of protein-protein or receptor-ligand interactions
Aptamer–drug conjugates (ApDCs)
Aptamer-siRNA conjugates
Aptamer bi-specifics
Aptamer (GRX1461) inhibits BXPC3 tumor growth in a dose dependent manner
Highest dose is equivalent to gemcitabine
Aptamer toxin conjugate (GRX1462) has improved potency
Highest dose completely inhibits tumor growth
© 2023 Guardian Therapeutics. All rights reserved.
Welcome to the Guardian Therapeutics and Band Therapeutics website. We do not use any cookies or other technologies on this website, except those that are strictly necessary to enable normal functioning of this web page. View our data protection statement.
Headquarters
Guardian Therapeutics
101 Hartwell Avenue
Suite 2
Lexington, MA 02421
+1 (781) 918-6580
General Inquiries:
info@guardian-rx.com
Business Development Inquiries: businessdevelopment@guardian-rx.com